A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Efficacy and Safety of Upadacitinib in Adult and Adolescent Subjects With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Latest Information Update: 11 Apr 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Hidradenitis suppurativa
- Focus Registrational; Therapeutic Use
- Acronyms Step-Up HS
- Sponsors AbbVie
- 14 Feb 2025 Planned primary completion date changed from 1 Oct 2025 to 1 Feb 2026.
- 25 Nov 2024 Planned primary completion date changed from 24 Nov 2025 to 1 Oct 2025.
- 24 Jul 2023 According to AbbVie media release, the first patient has been dosed in this trial and aims to enroll approximately 1,300 participants across 275 sites worldwide.